Eton Pharmaceuticals (ETON) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Eton Pharmaceuticals (ETON) is set to announce its Q2 2025 earnings on August 7th, with analysts expecting a loss of ($0.02) per share and revenue of $16.71 million.
• The company's stock has exhibited a 12-month price range between $3.25 and $21.48, and currently has a market cap of $389.43 million.
• Recently, insider David Krempa sold 10,223 shares, reducing his position by 1.64%, while institutional investors have significantly increased their stakes in Eton Pharmaceuticals.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) is expected to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Eton Pharmaceuticals to post earnings of ($0.02) per share and revenue of $16.71 million for the quarter.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 3.15% and a negative net margin of 9.49%. The firm had revenue of $17.28 million during the quarter, compared to analysts' expectations of $14.33 million. On average, analysts expect Eton Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Eton Pharmaceuticals Price Performance

NASDAQ ETON traded down $0.03 during trading hours on Friday, hitting $14.13. The company had a trading volume of 249,492 shares, compared to its average volume of 425,198. Eton Pharmaceuticals has a 52 week low of $3.25 and a 52 week high of $21.48. The firm has a 50 day simple moving average of $15.29 and a 200 day simple moving average of $15.43. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.43 and a current ratio of 1.97. The firm has a market capitalization of $378.97 million, a price-to-earnings ratio of -78.50 and a beta of 1.13.

Wall Street Analyst Weigh In

Several brokerages have commented on ETON. HC Wainwright restated a "buy" rating and issued a $35.00 target price (up previously from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th. B. Riley restated a "buy" rating and issued a $26.00 target price (up previously from $24.00) on shares of Eton Pharmaceuticals in a research note on Friday, May 16th. Finally, Craig Hallum raised their target price on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research note on Wednesday, May 14th.

Insider Activity

In other news, insider David Krempa sold 10,223 shares of Eton Pharmaceuticals stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $14.73, for a total transaction of $150,584.79. Following the completion of the sale, the insider owned 612,646 shares in the company, valued at approximately $9,024,275.58. This trade represents a 1.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 34,000 shares of company stock worth $504,318. Company insiders own 16.03% of the company's stock.

Institutional Trading of Eton Pharmaceuticals

Large investors have recently modified their holdings of the business. Millennium Management LLC boosted its position in shares of Eton Pharmaceuticals by 156.3% during the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company's stock valued at $4,620,000 after acquiring an additional 217,042 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Eton Pharmaceuticals by 34.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company's stock valued at $2,274,000 after acquiring an additional 45,341 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of Eton Pharmaceuticals by 49.1% during the 1st quarter. Jane Street Group LLC now owns 95,919 shares of the company's stock valued at $1,245,000 after buying an additional 31,596 shares in the last quarter. Institutional investors own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.